Skip to content

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

NRIX Nurix Therapeutics, Inc. Common stock
$26.71 -0.89% -0.24
Notify me if price changes either direction
Interactive Brokers Logotype

Buy NRIX stocks now with Interactive Brokers – the most advanced investment platform

Contents
  • Performance
  • Key stats
  • Financials
  • US politician trades
Loading

Key Stats

Market cap. 2.8B
Enterprise value 2.4B
Trailing PE -8.7459013892002
Forward PE -18.728415
PEG Ratio -0.15682305939255
Enterprise to EBITDA -6.828
Enterprise to revenue 65.591
Price to book MRQ 6.9405103
Price to sales TTM 76.07345

Financials

Fiscal Year Ends 2025-11-30
Most Recent Quarter (MRQ) 2026-05-31
Revenue (TTM) 36.8M
EBITDA -353180000
Diluted EPS TTM -3.55
Total Cash (MRQ) 443.5M
Current ratio (MRQ) 6.338
Operating Cash Flow (TTM) -293704000

NRIX trades by the US politicians

Percentage
0% 0 sells
100% 0 buys
Amount
$0 0 sells
$0 0 buys
In the last 0 months

Recent NRIX News

Home

IMPORTANT NOTICE

Finbold is a news and information website. This Site may contain sponsored content, advertisements, and third-party materials, for which Finbold expressly disclaims any liability.

RISK WARNING: Cryptocurrencies are high-risk investments and you should not expect to be protected if something goes wrong. Don’t invest unless you’re prepared to lose all the money you invest. (Click here to learn more about cryptocurrency risks.)

By accessing this Site, you acknowledge that you understand these risks and that Finbold bears no responsibility for any losses, damages, or consequences resulting from your use of the Site or reliance on its content. Click here to learn more.